logo
Plus   Neg
Share
Email

Bristol-Myers Squibb Boosts FY19 Adj. EPS Outlook - Quick Facts

While reporting financial results for the third quarter on Thursday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) slashed its earnings guidance for the full-year 2019, while raising full year adjusted earnings outlook.

For fiscal 2019, the company now projects earnings in a range of $3.46 to $3.56 per share and adjusted earnings in a range of $4.25 to $4.35 per share.

Previously, the company expected earnings in the range of $3.73 to $3.83 per share and adjusted earnings in the range of $4.20 to $4.30 per share.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $4.28 per share for the year. Analysts' estimates typically exclude special items.

The company said it continues to advance the planned acquisition of Celgene and the transaction closing. The company added that the guidance inclusive of the Celgene acquisition will be provided after the close of the transaction.

For the third quarter, the company reported net earnings attributable to Bristol-Myers Squibb of $1.35 billion, or $0.83 per share, down from $1.90 billion, or $1.16 per share in the prior-year quarter. Adjusted net earnings per share attributable to Bristol-Myers Squibb were $1.17, compared to last year's $1.09.

Bristol-Myers Squibb posted third-quarter revenues of $6.01 billion, an increase of 6 percent from the same period a year ago. Revenues increased 7 percent when adjusted for foreign exchange impact.

Analysts expected quarterly earnings of $1.07 per share on revenues of 5.89 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Boy Scouts of America recalled about 78,000 units of Cub Scout outdoor activity pins for violating the federal lead content ban, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the activity pin's face and shaft contain levels of lead that exceed the federal lead content ban. Lead is toxic if ingested by young children and can cause adverse health issues. McDonald's Corp. is delaying the reopening of all dine-in services in its U.S. restaurants by 21 days due to the increase in coronavirus cases across the country, reports said citing an internal letter. The burger chain said, "Our resiliency will be tested again. COVID-19 cases are on the rise." The U.S. Department of Health and Human Services or HHS said it has secured most of the supply of COVID-19 drug remdesivir through September. The deal would allow American hospitals to purchase the antiviral drug in allocated amounts amid the spike in confirmed cases each day. HHS Secretary Alex Azar said, "President Trump has struck an amazing deal to ensure Americans have access to the first..."
Follow RTT